Vera Therapeutics (VERA) EBITDA (2020 - 2026)

Vera Therapeutics has reported EBITDA for 7 years, with the latest figure at -$122.0 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 137.15% year-over-year to -$122.0 million; the trailing twelve-month figure through Mar 2026 stood at -$369.8 million (down 111.74% YoY), and the FY2025 full-year result was -$299.2 million, down 96.85% from the prior year.
• EBITDA for Q1 2026 stood at -$122.0 million, down from -$91.2 million in the prior quarter.
• The five-year high for EBITDA was -$15.0 million in Q2 2022, with the low at -$122.0 million in Q1 2026.
• Historically, EBITDA has averaged -$44.6 million across 5 years, with a median of -$32.4 million in 2022.
• Annual changes were most pronounced in 2022 — EBITDA tumbled 260.92% — and 2023, when it grew 21.09%.
• Vera Therapeutics' EBITDA stood at -$32.4 million in 2022, then gained by 21.09% to -$25.6 million in 2023, then tumbled by 72.49% to -$44.1 million in 2024, then tumbled by 106.9% to -$91.2 million in 2025, then sank by 33.76% to -$122.0 million in 2026.
• The last three EBITDA figures came in at -$122.0 million (Q1 2026), -$91.2 million (Q4 2025), and -$79.9 million (Q3 2025), per Business Quant data.